跳至主要内容
临床试验/NCT03875937
NCT03875937已完成1 期

Pharmacokinetics of Intramuscular Tranexamic Acid in Trauma Patients: a Clinical Trial

London School of Hygiene and Tropical Medicine2 个研究点 分布在 1 个国家目标入组 31 人开始时间: 2019年9月17日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
31
试验地点
2
主要终点
Concentration of serum TXA concentrations over time.

研究概览

简要总结

Intramuscular injection of tranexamic acid (TXA) would increase its use in situations where administration of intravenous drugs is difficult. The investigators aim to assess the population pharmacokinetics of intramuscular TXA in trauma patients.

Primary endpoint: Serum TXA concentrations over time. Secondary endpoints: Local reactions at injection sites and adverse events

详细描述

A prospective, open-label, multicentre, pharmacokinetic study conducted in the UK hospital. Potential eligible patients will have received a 1 gram IV dose of TXA at the scene of the injury or on arrival in hospital and a second dose is clinically indicated.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
16 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult (appear to be at least 16 years old) trauma patients who have received 1 gram of intravenous TXA for the management of haemorrhage in whom a second dose is clinically indicated are eligible.

排除标准

  • 未提供

研究组 & 干预措施

Tranexamic acid 1 gram intramuscularly

Experimental

Patients will receive a 1 gram dose of TXA by IM injection at least 1 hour and 30 minutes after their initial IV injection received at the scene or on arrival to hospital. The IM dose will be given as two 5mL (0.5 gram each) injections into the thigh (rectus femoris or vastus lateralis), gluteal or deltoid muscles, depending on the clinical scenario (e.g. taking into account the type of injury). Injections should be given in a non-injured muscle.

干预措施: Tranexamic 1 gram (Drug)

结局指标

主要结局

Concentration of serum TXA concentrations over time.

时间窗: Blood samples will be taken pre-dose and up to 11 hours after IM TXA

次要结局

  • Number of participants with Injection sites reactions(death, discharge or day seven (whichever comes first))
  • Number of adverse events reported by type(death, discharge or day 7 (whichever comes first))

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验